REGENXBIO Inc. (NASDAQ:RGNX) insider Kenneth T. Mills sold 10,000 shares of REGENXBIO stock in a transaction that occurred on Monday, May 21st. The shares were sold at an average price of $47.05, for a total transaction of $470,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of REGENXBIO opened at $49.45 on Friday, Marketbeat.com reports. REGENXBIO Inc. has a 1-year low of $16.30 and a 1-year high of $51.20. The firm has a market capitalization of $1.51 billion, a PE ratio of -20.18, a PEG ratio of 25.25 and a beta of -1.23.
REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported $3.04 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.00 by $2.04. REGENXBIO had a net margin of 37.28% and a return on equity of 23.27%. The business had revenue of $132.39 million during the quarter, compared to analysts’ expectations of $80.00 million. research analysts anticipate that REGENXBIO Inc. will post 0.61 EPS for the current fiscal year.
Several institutional investors have recently modified their holdings of the company. Redmile Group LLC lifted its stake in shares of REGENXBIO by 49.5% in the first quarter. Redmile Group LLC now owns 2,130,972 shares of the biotechnology company’s stock worth $63,610,000 after buying an additional 705,700 shares during the last quarter. RTW Investments LP lifted its stake in shares of REGENXBIO by 1.4% in the fourth quarter. RTW Investments LP now owns 1,561,210 shares of the biotechnology company’s stock worth $51,910,000 after buying an additional 22,205 shares during the last quarter. Citadel Advisors LLC lifted its stake in shares of REGENXBIO by 62.2% in the fourth quarter. Citadel Advisors LLC now owns 987,752 shares of the biotechnology company’s stock worth $32,843,000 after buying an additional 378,612 shares during the last quarter. Artal Group S.A. lifted its stake in shares of REGENXBIO by 56.3% in the fourth quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock worth $8,313,000 after buying an additional 90,000 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of REGENXBIO by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 248,328 shares of the biotechnology company’s stock worth $8,256,000 after buying an additional 2,506 shares during the last quarter. Institutional investors and hedge funds own 69.26% of the company’s stock.
RGNX has been the subject of a number of analyst reports. BidaskClub cut shares of REGENXBIO from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Mizuho initiated coverage on shares of REGENXBIO in a research note on Monday, February 12th. They issued a “neutral” rating and a $28.00 target price for the company. Zacks Investment Research upgraded shares of REGENXBIO from a “hold” rating to a “buy” rating and set a $33.00 target price for the company in a research note on Thursday, March 8th. Morgan Stanley reduced their target price on shares of REGENXBIO from $36.00 to $35.00 and set an “overweight” rating for the company in a research note on Wednesday, March 14th. Finally, ValuEngine upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research note on Wednesday, April 4th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $43.25.
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.